Navigation Links
BioMedical Enterprises, Inc. (BME) Announces the Appointment of Keith M. Peeples as Vice President, Sales and Marketing
Date:3/30/2009

SAN ANTONIO, March 30 /PRNewswire/ -- BioMedical Enterprises, Inc. (BME), a rapidly growing medical device company focused on the clinical development of orthopaedic memory metal implants, announced today that it has appointed Keith M. Peeples as its Vice President, Sales and Marketing.

BME specializes in nitinol implants that contract and compress bone after implantation, bringing bone ends together to promote bone union. The Orthopaedic Staple System (OSS)(TM) of proprietary staples and the patented OSSforce(TM) Controller allow the surgeon to finely control the amount of compression and rate of force application generated on bones, thereby reducing fractures and stimulate bone healing.

"Keith is a proven executive who brings extensive senior level sales and marketing experience to BME, as well as a shared strategic vision to create a leading medical device company," said Kenneth I. Moch, President and CEO of BME. "We are delighted to have Keith as part of our leadership team."

Mr. Peeples brings to BME over 25 years experience in sales, marketing and sales training in the healthcare industry. Prior to joining BME he was Vice President of Sales and Marketing at Advanced Bio-Surfaces, Inc., an orthopedic company that manufactures an interpositional knee implant system. From 1999 to 2006, Mr. Peeples was Vice President of Sales at The ASC Network, which offers a supply solution to physician owned or procedure based centers. From 1995-1998, Mr. Peeples was Director of Sales for North and South America at Medtronic / InStent, a provider of self-expanding nitinol stents for gastroenterology, urology, radiology and peripheral vascular procedures. Mr. Peeples also worked as the Western Regional Sales Manager and as an independent sales representative with Pentax Precision Instrument Corp., a provider of flexible endoscopes, from 1981 to 1995. Mr. Peeples has a B.A. in Biology from the Washington University in St. Louis, MO.

About BioMedical Enterprises, Inc.

BME designs, manufactures and markets memory metal implants used in orthopaedic reconstructive surgery and fracture management. BME's Orthopaedic Staple System (OSS)(TM) utilizes the unique properties of the shape memory alloy nitinol to provide controlled long-term compression that enhances the body's natural healing process in an effort to achieve faster healing times and fewer complications. BME's barbed and smooth OSStaple(TM) and Step OSStaple(TM) lines of bone fusion implants, along with the contoured OSSArc(TM), are designed to achieve controlled long-term compression of bone fragments. BME's OSSAnchor(TM) line of soft tissue fixation implants gives surgeons a simple yet powerful tool to attach soft tissue to bone. These implants are an integral part of BME's proprietary compression and fixation system activated by the patented OSSforce(TM) Implant Controller.

Web site: http://www.bme-tx.com


'/>"/>
SOURCE BioMedical Enterprises, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
2. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
3. Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test
4. SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market
5. NCIIA Announces Launch of 4th Annual Student Biomedical Innovation Competition
6. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
7. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
8. Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter
9. Environmental Tectonics Corporations BioMedical Division Announces New Contract
10. Avery Biomedical Devices, Inc. Appoints Elefteriades to its Board of Directors
11. Verax Biomedical Receives ISO Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from ... believe could be a new and helpful biomarker for malignant pleural mesothelioma. Surviving ... to read it now. , Biomarkers are components in the blood, tissue ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):